From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now

Area of Science:

• Hepatocellular carcinoma (HCC) research
• Molecular oncology
• Targeted cancer therapy

Background:

• Hepatocellular carcinoma (HCC) exhibits high chemoresistance and poor prognosis despite existing therapies.
• Limited effective systemic treatment options and adjuvant therapies are available for HCC.
• Recent advancements have elucidated the molecular pathways driving HCC carcinogenesis and progression.

Purpose of the Study:

• To review the molecular biology of hepatocellular carcinoma (HCC).
• To discuss the development and testing of targeted agents for HCC.
• To highlight the emerging role of molecular targeting therapy in advanced HCC management.

Main Methods:

• Review of recent research on HCC molecular pathways, including Ras/Raf/Mek/Erk and PI3k/Akt/mTOR.
• Analysis of preclinical studies involving HCC cell lines and xenograft models.
• Evaluation of clinical trial data for agents targeting molecular abnormalities in HCC.

Main Results:

• Key signaling pathways and growth/angiogenic factors (EGF, VEGF) implicated in HCC identified.
• Preclinical development of targeted agents against these molecular abnormalities.
• Sorafenib, a multikinase inhibitor, demonstrated efficacy in prolonging survival in advanced HCC patients.

Conclusions:

• The management of advanced hepatocellular carcinoma (HCC) is transitioning towards molecularly targeted therapies.
• Targeted therapy represents a significant advancement given the lack of effective systemic treatments for HCC.
• Further research and clinical application of targeted agents are crucial for improving HCC outcomes.